title: Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice.
abstract: Apolipoprotein(a) (apo(a)), the distinguishing protein of atherogenic lipoprotein(a), directs accumulation of the lipoprotein(a) particle to sites in the arterial wall where atherosclerotic lipid lesions develop in man and in transgenic mice expressing human apo(a). It has been proposed that focal apo(a) accumulation in the transgenic mouse vessel wall causes the observed severe local inhibition of transforming growth factor-beta (TGF-beta) activity and the consequent activation of the smooth muscle cells, which subsequently accumulate lipid to form lesions if the mice are fed a high fat diet. We show that blocking formation of these vascular lesions by two independent mechanisms, tamoxifen treatment and increasing high density lipoprotein, also abolishes apo(a) accumulation, inhibition of TGF-beta activity, and activation of smooth muscle cells. The data are consistent with a feedback mechanism in which an initial accumulation of apo(a) inhibits local TGF-beta activity, leading to further accumulation of apo(a). Breaking the feedback loop prevents smooth muscle cell activation and therefore lipid lesion development.
authors.affiliation: Falk Cardiovascular Research Center, Stanford University, Stanford, California 94305-5246, USA. richard.lawn@forsythe.stanford.edu
authors.forename: R M
authors.initials: RM
authors.lastname: Lawn
authors.forename: A D
authors.initials: AD
authors.lastname: Pearle
authors.forename: L L
authors.initials: LL
authors.lastname: Kunz
authors.forename: E M
authors.initials: EM
authors.lastname: Rubin
authors.forename: J
authors.initials: J
authors.lastname: Reckless
authors.forename: J C
authors.initials: JC
authors.lastname: Metcalfe
authors.forename: D J
authors.initials: DJ
authors.lastname: Grainger
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000378:metabolism; D001054:Apolipoproteins A / Q000378:metabolism*; D002454:Cell Differentiation; D004041:Dietary Fats / Q000009:adverse effects; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D009131:Muscle, Smooth, Vascular / Q000378:metabolism* / Q000648:ultrastructure; D013629:Tamoxifen / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000378:metabolism*
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D004041:Dietary Fats; D008075:Lipoproteins, HDL; D016212:Transforming Growth Factor beta; D013629:Tamoxifen